TARGETED SLOW RELEASE ANTICARIES AGENT

靶向缓释防龋剂

• 批准号: 2537297
• 负责人: DANIEL A KERSCHENSTEINER
• 金额: $ 10万
• 依托单位: CHERRYSTONE INVESTMENTS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-02-15 至 1998-08-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2537297
• 关键词: Lactobacillus; Streptococcus mutans; antibiotics; collagen; dental caries inhibitor; lectin; method development; mouthwash; receptor binding; silver

The purpose of this proposal is to design and test in vitro and effective anticaries agent which target two major cariogenic bacteria-- Streptococcus mutants and lactobacilli spp.. The goal is to study and obtain the optimum functioning of a slowly-releasing antibacterial component having adequate bactericidal potency and low toxicity. This is linked together with receptor-specific proteins which target the cariogenic microorganisms. Two prime receptor candidates have been identified. One is a lectin-like protein, shown to expressly agglutinate Streptococcus mutants and the other is a protein found in dentin and dental root which mitigates the binding of lactobacillus spp. in this locale. The receptor specific proteins equip the united agent with 1) surgically precise specificity for binding only to the offending bacteria and 2) enhanced residence time of lethal operation for the suicidal linkup. A "cocktail" of combined bactericide-receptor-specific ligands is to be mixed proportionally according to results of outlined experiments designed to elicit the capabilities of the agents to: target or precisely bind only to the cariogenic bacteria; reside for a critical exposure period at the site of action, inhibit glycolysis of bacteria growing on a solid support; and kill bacteria residing on tooth-like hydroxyapatite. PROPOSED COMMERCIAL APPLICATION: The mouthrinse market is $2 billion in size. Except for one prescription brand, no one is effective in preventing or reducing the risk of dental caries.

该提案的目的是设计和测试体外和 针对两种主要致龋菌的有效防龋剂—— 链球菌突变体和乳杆菌属。目标是研究和 获得缓慢释放抗菌剂的最佳功能 具有足够的杀菌效力和低毒性的成分。这 与靶向受体的特异性蛋白质连接在一起 致龋微生物。两个主要候选受体已被 确定。一种是凝集素样蛋白，显示出明显凝集 链球菌突变体和另一种是在牙本质中发现的蛋白质 牙根可减轻乳酸菌的结合。在这个 语言环境。受体特异性蛋白质为联合制剂配备了 1) 外科手术般精确的特异性，仅与违规者结合 细菌和2）延长致死操作的停留时间 自杀式的联系。组合杀菌剂-受体特异性的“鸡尾酒” 配体将根据概述的结果按比例混合 旨在激发智能体以下能力的实验： 或仅与致龋菌精确结合；为关键而居住 在作用部位暴露一段时间，抑制细菌的糖酵解 在坚实的支撑下成长；并杀死牙齿上的细菌 羟基磷灰石。 拟议的商业应用： 漱口水市场规模达 20 亿美元。除一张处方外 品牌，没有人能够有效预防或降低牙科风险 龋齿。